Chelsea: Combined Northera Data Confirm Symptom Improvement In Patients With NOH

Chelsea Therapeutics To Present At ROTH Conference ; Webcast At 6:30 PM ET

Trade CHTP now with

6/21/2012 1:45 PM ET

Chelsea Therapeutics International, Ltd. (CHTP: Quote) announced results from an integrated dataset of two phase 3 studies, Study 301 and Study 302, which showed that patients treated with Northera (droxidopa) experienced improvements in their symptoms of Neurogenic Orthostatic Hypotension (also known as NOH or Neurogenic OH) as measured by the Orthostatic Hypotension Questionnaire (OHQ) composite score (p=0.001) and a number of individual symptoms, including dizziness (p=0.004).

The results, which include data from over 250 patients with symptomatic Neurogenic OH and diagnoses of Parkinson's disease, multiple system atrophy (MSA), pure autonomic failure (PAF), dopamine beta hydroxylase deficiency or nondiabetic autonomic neuropathy, were presented by Christopher Mathias, MD at the 16th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland.

Gregor Wenning, MD presented data showing that patients with pure autonomic failure and MSA showed statistically significant improvement in the OHQ composite score following droxidopa treatment versus placebo (p=0.022 and p=0.018, respectively). The data also showed that age is an important contributor to improvements seen in patients with Parkinson's disease. Parkinson's disease patients younger than 65 treated with droxidopa showed greater improvements versus placebo than those over 75 (1.63 units vs. -0.04 units).

Phillip Low, MD presented data from a post-hoc analysis which showed that 94 patients taking midodrine at screening presented with more severe condition at baseline as measured by OHQ composite score (6.7 vs. 5.8), yet after treatment with droxidopa, all patients had improvement in OHQ regardless of previous midodrine use.

To receive FREE breaking news email alerts for Chelsea Therapeutics International and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 131 Articles Next>>

Editors Pick

Stocks Move Higher On Comments From Fed Officials - U.S. Commentary

Stocks have moved mostly higher over the course of the trading day on Tuesday after showing a lack of direction earlier in the session. The major averages have climbed more firmly into positive territory, offsetting the modest losses posted in the previous session. The major averages have moved roughly sideways in recent trading, hovering near their new highs for the session.

Stocks Turning In Another Lackluster Performance - U.S. Commentary

Stocks have shown a lack of direction over the course of the trading day on Tuesday after failing to sustain an early upward move. The choppy trading extends the lackluster performance that was seen throughout the previous session. The major averages are currently posting modest gains but have pulled back off their highs for the session.

Obama's Approval Rating Holding Steady Despite Scandals

While a recent series of scandals have caused headaches for the White House, the results of a Washington Post-ABC News poll released Tuesday suggest that the news has not had an impact on President Barack Obama's approval rating. The poll showed that 51 percent of Americans approve of the way Obama is handling his job as president compared to 44 percent that disapprove.